PsA Treatment Options Expand

Phase 3 POETYK trial results support FDA approval of deucravacitinib for adults with active PsA.

Share

1

Deucravacitinib (Sotyktu) is the first TYK2 inhibitor approved for adults with active psoriatic arthritis by the FDA.
2

The drug demonstrated improved disease activity outcomes in two phase 3 trials compared to placebo.
3

In the POETYK PsA-1 trial, 54% of patients on deucravacitinib achieved ACR20 response versus 34% on placebo.
4

The safety profile of deucravacitinib was consistent with previous studies, with common adverse reactions including upper respiratory infections.
5

Deucravacitinib selectively inhibits TYK2 signaling, affecting interleukin-23, interleukin-12, and type 1 interferon pathways.